SCHEMBL4083787

SCHEMBL4083787

CCCCCCCCCCCCOS(=O)(=O)OC(=O)C(O)CO.[NaH]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 9/20 0.42
CA2 P00918 9/20 0.42
CA9 Q16790 8/20 0.42
CA12 O43570 3/20 0.42
CA7 P43166 3/20 0.42
CA14 Q9ULX7 3/20 0.42
CA3 P07451 2/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
NAAA Q02083 1/20 0.42
RECQL P46063 2/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
EPHX2 P34913 1/20 0.41
BLM P54132 1/20 0.41
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8824233 1.00 CA1 (0.42) CA1CA2CA9CA12CA7
SCHEMBL8099158 0.98 CA1 (0.43) CA1CA2CA9CA12CA7
Ammonia Solution, Strong SCHEMBL8824248 0.97 CA1 (0.42) CA1CA2CA9CA12CA7
SCHEMBL21058283 0.97 CA1 (0.42) CA1CA2CA9CA12CA7
Ammonia Solution, Strong SCHEMBL8824130 0.97 CA1 (0.42) CA1CA2CA9CA12CA7
SCHEMBL8824122 0.97 CA1 (0.42) CA1CA2CA9CA12CA7
Ether SCHEMBL11758020 0.94 USP2 (0.39) CA1CA2CA9CA12CA7
Ether SCHEMBL4598201 0.93 USP2 (0.40) CA1CA2CA9CA12CA7
SCHEMBL11222011 0.92 DGKA (0.46)
E968 SCHEMBL8062338 0.91 USP2 (0.36) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090214648-A1 PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE DR. REDDY'S LABORATORIES, INC. 2009-08-27 US claimed
US-5393461-A For use in cosmetics, paints, drugs,inks; mixing powder with anionic, cationic, amphoteric, nonionic surfactants, oils, solvents, wetting agents and water, emulsification RTD CORPORATION (US) 1995-02-28 US claimed
US-12589058-B2 Method of dispersing hydrophobic substances in aqueous cleansing system RENMATIX, INC. (US) 2026-03-31 US disclosed
US-20240082117-A1 Method of Dispersing Hydrophobic Substances in Aqueous Cleansing System RENMATIX INC (US) 2024-03-14 US disclosed
US-20210386631-A1 Method of Dispersing Hydrophobic Substances in Aqueous Cleansing System RENMATIX, INC. 2021-12-16 US disclosed
WO-2021251987-A1 METHOD OF DISPERSING HYDROPHOBIC SUBSTANCES IN AQUEOUS CLEANSING SYSTEM RENMATIX, INC. (US) 2021-12-16 WO disclosed
US-20090214648-A1 PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE DR. REDDY'S LABORATORIES, INC. 2009-08-27 US disclosed
US-20090030060-A1 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH METRONIDAZOLE COMPOSITIONS TOLMAR, INC. (US) 2009-01-29 US disclosed
US-20080255498-A1 Sensitizer Solutions, Systems, and Methods of Use OROSCIENCE, INC. 2008-10-16 US disclosed
EP-1933941-A2 TREATMENT SYSTEMS FOR DELIVERY OF SENSITIZER SOLUTIONS Houle, Philip R. (US) 2008-06-25 EP disclosed
US-20070231358-A1 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH METRONIDAZOLE COMPOSITIONS TOLMAR, INC. 2007-10-04 US disclosed
US-5393461-A For use in cosmetics, paints, drugs,inks; mixing powder with anionic, cationic, amphoteric, nonionic surfactants, oils, solvents, wetting agents and water, emulsification RTD CORPORATION (US) 1995-02-28 US disclosed
EP-0404376-B1 Buffered metronidazole compositions for intravaginal treatment of vaginal infections CURATEK PHARMACEUTICALS (US) 1994-03-23 EP disclosed
EP-0404376-A2 Buffered metronidazole compositions for intravaginal treatment of vaginal infections CURATEK PHARMACEUTICALS Limited Partnership (US) 1990-12-27 EP disclosed
WO-1990014832-A1 IMPROVED INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS CURATEK PHARMACEUTICALS LIMITED PARTNERSHIP (US) 1990-12-13 WO disclosed
US-4508634-A REMOVAL OF PAINT, GREASE AND DIRT MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1985-04-02 US disclosed
US-4220152-A Delivery system PFIZER INC. (US) 1980-09-02 US disclosed
US-4220153-A Controlled release delivery system PFIZER INC. (US) 1980-09-02 US disclosed
US-4033895-A Non-irritating shampoo compositions containing stearyl amine oxide REVLON, INC. (US) 1977-07-05 US disclosed
US-4017615-A ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS SYNTEX CORPORATION (PM) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12589058-B2 Method of dispersing hydrophobic substances in aqueous cleansing system LIPA, STS, CEL CA1 3902/4885CA2 2199/4885CA9 2688/4885
US-20090214648-A1 PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE HRH1, HRH4, HRH2 CA1 3701/4885CA2 1164/4885CA9 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.